Trials / Active Not Recruiting
Active Not RecruitingNCT05653492
Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease
Safety, Feasibility, and Tolerability of Sulforaphane in Children with CKD
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 1 Year – 17 Years
- Healthy volunteers
- Not accepted
Summary
This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to SFN supplementation in this population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sulforaphane | Dosing study one to four 30 mg/d tablets depending on weight |
Timeline
- Start date
- 2023-05-15
- Primary completion
- 2025-04-30
- Completion
- 2025-12-31
- First posted
- 2022-12-16
- Last updated
- 2024-09-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05653492. Inclusion in this directory is not an endorsement.